Muscarinic antagonists

Last updated: September 12, 2024

Muscarinic antagonists

Watch later

Watch later

Somatostatin
Synthesis of adrenocortical hormones
Cortisol
Testosterone
Estrogen and progesterone
Phosphate, calcium and magnesium homeostasis
Parathyroid hormone
Vitamin D
Calcitonin
Congenital adrenal hyperplasia
Primary adrenal insufficiency
Waterhouse-Friderichsen syndrome
Hyperaldosteronism
Adrenal cortical carcinoma
Cushing syndrome
Conn syndrome
Thyroglossal duct cyst
Hyperthyroidism
Graves disease
Thyroid eye disease (NORD)
Toxic multinodular goiter
Thyroid storm
Hypothyroidism
Euthyroid sick syndrome
Hashimoto thyroiditis
Subacute granulomatous thyroiditis
Riedel thyroiditis
Thyroid cancer
Hyperparathyroidism
Hypoparathyroidism
Hypercalcemia
Hypocalcemia
Diabetes mellitus
Diabetic retinopathy
Diabetic nephropathy
Hyperpituitarism
Pituitary adenoma
Hyperprolactinemia
Prolactinoma
Gigantism
Acromegaly
Hypopituitarism
Pituitary apoplexy
Sheehan syndrome
Hypoprolactinemia
Constitutional growth delay
Diabetes insipidus
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Precocious puberty
Delayed puberty
Premature ovarian failure
Polycystic ovary syndrome
Androgen insensitivity syndrome
Kallmann syndrome
5-alpha-reductase deficiency
Autoimmune polyglandular syndrome type 1 (NORD)
Multiple endocrine neoplasia
Pancreatic neuroendocrine neoplasms
Zollinger-Ellison syndrome
Pheochromocytoma
Neuroblastoma
Opsoclonus myoclonus syndrome (NORD)
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Parathyroid disorders and calcium imbalance: Pathology review
Diabetes mellitus: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Pituitary tumors: Pathology review
Hypopituitarism: Pathology review
Diabetes insipidus and SIADH: Pathology review
Multiple endocrine neoplasia: Pathology review
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Bones of the cranium
Anatomy of the cranial base
Anatomy of the orbit
Anatomy of the eye
Bones of the neck
Superficial structures of the neck: Cervical plexus
Superficial structures of the neck: Anterior triangle
Deep structures of the neck: Prevertebral muscles
Anatomy of the thyroid and parathyroid glands
Anatomy of the larynx and trachea
Anatomy of the pharynx and esophagus
Introduction to the cranial nerves
Anatomy of the olfactory (CN I) and optic (CN II) nerves
Anatomy of the oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves
Nasal cavity and larynx histology
Anatomy and physiology of the eye
Photoreception
Optic pathways and visual fields
Anatomy and physiology of the ear
Auditory transduction and pathways
Vestibular transduction
Vestibulo-ocular reflex and nystagmus
Olfactory transduction and pathways
Taste and the tongue
Glaucoma
Retinoblastoma
Laryngomalacia
Laryngitis
Bacterial epiglottitis
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Vertigo: Pathology review
Nasal, oral and pharyngeal diseases: Pathology review
Antihistamines for allergies
Acid reducing medications
Blood histology
Sepsis
Anaphylaxis
Food allergy
Blood products and transfusion: Clinical
Bites and stings: Clinical
Hematopoietic medications
Thrombolytics
Hemophilia
The nurse and doctor and the avoidable lawsuit (Coverys)
Traumatic brain injury: Pathology review
Concussion and traumatic brain injury
Traumatic brain injury: Clinical
Brain herniation
Drug administration and dosing regimens
Sympathomimetics: Direct agonists
Muscarinic antagonists
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Laxatives and cathartics
Antidiarrheals
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Glucocorticoids
Opioid agonists, mixed agonist-antagonists and partial agonists
Nonbenzodiazepine anticonvulsants
Migraine medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Opioid antagonists
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
PDE5 inhibitors
Estrogens and antiestrogens
Progestins and antiprogestins
Androgens and antiandrogens
Aromatase inhibitors
Uterine stimulants and relaxants
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines

Transcript

Watch video only

Muscarinic antagonists, or antimuscarinic medications, are a class of medications that prevent muscarinic receptors of the parasympathetic nervous system from getting stimulated by acetylcholine.

Okay, first things first, the nervous system is divided into the central nervous system, so the brain and spinal cord; and the peripheral nervous system.

The peripheral nervous system can be divided into the somatic nervous system, which controls voluntary movement of our skeletal muscles; and the autonomic nervous system, which is further divided into the sympathetic and parasympathetic nervous systems, and controls the involuntary movement of the smooth muscles, and the glands of our organs.

Now, the autonomic nervous system is made up of a relay that includes two neurons.

We’ll focus on just the parasympathetic nervous system.

Signals for the parasympathetic nervous system start in the hypothalamus.

These hypothalamic neurons synapse with nuclei in the brainstem or spinal cord, which send out signals to preganglionic neurons that travel to the rest of the body.

Their targets are the parasympathetic ganglion, which consist of many postganglionic neuron cell bodies and are located nearby or directly in the target organs.

The postganglionic neurons extend the rest of the way to the target cell, where they release the neurotransmitter acetylcholine, which is why they are also called cholinergic neurons.

Acetylcholine binds to a type of receptor, known as muscarinic receptors, on the cells of target organs, which allow the parasympathetic nervous system to trigger a ‘rest and digest’ response, meaning that it keeps body-energy use as low as possible to stimulate activities like digestion.

It acts in the heart, slowing the heart rate and reducing the cardiac output.

In the gastrointestinal tract, it increases its motility to stimulate digestion and defecation.

In the bladder, it causes constriction of the bladder muscle, called the detrusor muscle, which stimulates urination.

In salivary, sweat, and lacrimal glands, it increases their secretions.

In the liver, it triggers glucose storage to reduce blood glucose levels.

In the lungs, it causes bronchoconstriction, since in a relaxed state our cells do not consume as much oxygen.

In the eyes, it triggers miosis, or constriction of the pupils, to improve close vision and stimulates the contraction of the ciliary muscles, increasing the outflow of aqueous humor, which is the fluid in the anterior chamber of the eye, and this decreases the intraocular pressure.

Finally, its effects on the brain are extremely complicated, but generally, they cause overall stimulation, and they participate in many wanted and unwanted functions, such as movement control and vomiting, respectively.

Alright, so medications that block the effects of acetylcholine on muscarinic receptors are called muscarinic antagonists or antimuscarinic medications.

Now, the most famous muscarinic antagonist is atropine.

Atropine blocks the “rest and digest” effect from the parasympathetic system, so clinically, it can be used to treat bradycardia, or slowed heart rate.

It decreases bladder smooth muscle contraction so it’s useful for preventing nocturnal enuresis, or bedwetting, in children.

Ophthalmologists can also use atropine to dilate the pupils.

Finally, it’s an antidote for poisoning by anticholinesterases like organophosphates found in pesticides. These agents prolong the effect of acetylcholine by inhibiting their break down, so atropine can help by simply blocking the muscarinic receptors.

Now, for side effects, atropine can produce: tachycardia, or increased heart rate; constipation and urinary retention; dry mouth, skin and eyes; and blurry vision.

The more severe side effects include hyperthermia, dizziness, confusion, and delirium.

It’s also contraindicated in individuals suffering from narrow angle glaucoma since it can worsen the obstruction of aqueous humor drainage.

Key Takeaways

Muscarinic antagonists, also known as antimuscarinic medications, are a class of drugs that block the activation of muscarinic receptors of the parasympathetic nervous system. Examples of muscarinic antagonists include atropine, scopolamine, and ipratropium. These drugs are used to treat a variety of conditions, such as asthma, glaucoma, and urinary incontinence. They can also be used to treat the symptoms of poisoning from organophosphate insecticides.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Muscarinic receptor subtypes in airways" Life Sci (1993)
  5. "Pharmacologic therapy of obstructive airway disease" Clin Chest Med (1990)
  6. "[Atropine. Principles and rules of utilization]" Rev Prat (2001)
  7. "Antimuscarinic drugs" Prof Nurse (2004)